Loading clinical trials...
Loading clinical trials...
The Effect Of Methylnaltrexone (Relistor™) on Gut Motility and Tolerance to Tube Feeding in Patients Treated With Opiate Therapy
It is hypothesized that using methylnaltrexone in addition to pain killer narcotics (opiates) in patients will result in increased tube feeding rates with more frequent nutrition at goal calorie rate.
Tube feeding rates and tube feeding residual volumes will be measured and followed blinded to the treatment arm (methylnaltrexone vs. placebo) to evaluate if patients (who prior to study entry did not tolerate goal rates tube feeds) can get closer to tube feeding goal with the treatment arm.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hahnemann University Hospital
Philadelphia, Pennsylvania, United States
Cancer Treatment Center of America
Philadelphia, Pennsylvania, United States
Start Date
October 1, 2010
Primary Completion Date
May 1, 2012
Completion Date
May 1, 2012
Last Updated
March 17, 2015
Methylnaltrexone
DRUG
Saline injection
DRUG
Lead Sponsor
Drexel University
Collaborators
NCT04030871
NCT07441746
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06717321